Anti-CD3 clinical trials in type 1 diabetes mellitus
| Autor: | Kevan C. Herold, Anastasia G. Daifotis, Scott Koenig, Lucienne Chatenoud |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Adolescent CD3 Complex medicine.medical_treatment T-Lymphocytes Immunology Receptors Fc Antibodies Monoclonal Humanized chemistry.chemical_compound medicine Immunology and Allergy Humans Hypoglycemic Agents Insulin Dosing Adverse effect Child Infusions Intravenous Type 1 diabetes Clinical Trials as Topic Teplizumab C-Peptide C-peptide business.industry Age Factors Otelixizumab Middle Aged medicine.disease Clinical trial Diabetes Mellitus Type 1 chemistry Female business medicine.drug |
| Zdroj: | Clinical immunology (Orlando, Fla.). 149(3) |
| ISSN: | 1521-7035 |
| Popis: | Two humanized, anti-CD3 mAbs with reduced FcR binding, teplizumab and otelixizumab, have been evaluated in over 1500 subjects, ages 7-45, with new and recently diagnosed T1D with a range of intravenous doses (3-48mg) and regimens (6-14 days, single or repeat courses). In general, studies that used adequate dosing demonstrated improvement in stimulated C-peptide responses and reduced need for exogenous insulin for two years and even longer after diagnosis. Drug treatment causes a transient reduction in circulating T cells, but the available data suggest that the mechanism of action may involve induction of regulatory mechanisms. The adverse effects of anti-CD3 treatment are infusion-related and transient. The studies have identified significant differences in efficacy among patient groups suggesting that a key aspect for development of this immune therapy is identification of the demographic, metabolic, and immunologic features that distinguish subjects who are most likely to show beneficial clinical responses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect